What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers Marco Meglio

Published Date: 20 Dec 2025

Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Positive Survival Data in Lung Cancer With Perioperative Therapy

2.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

3.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

4.

For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.

5.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot